# Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

> **NCT05897424** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 185 (estimated)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency
- Emphysema

## Interventions

- **DRUG:** SAR447537

## Key facts

- **NCT ID:** NCT05897424
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 185 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05897424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05897424, "Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05897424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*